FTSE MIB
33.621,27 -85,94 (-0,25%) Dow Jones
39.112,16 -299,05 (-0,76%) Nasdaq
17.717,65 +220,84 (+1,26%) Nikkei 225
39.667,07 +493,92 (+1,26%) Petrolio
81,58 +0,75 (+0,93%) Bitcoin EUR
57.284,36 -44,86 (-0,08%)
CRMD Sep 2024 8.000 put
| Chiusura precedente | 2,7300 |
| Aperto | N/D |
| Denaro | 2,7500 |
| Domanda | 3,7000 |
| Prezzo d'esercizio | 8,00 |
| Scadenza | 2024-09-20 |
| Min-Max giorno | 2,7300 - 2,7300 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1 |
GlobeNewswireCorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference
BERKELEY HEIGHTS, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that an abstract has been accepted for presentation at the IDWeek 2023 meeting being held in Boston, Massachusetts, October 11 – 15. The abstract being presented highlights data regarding in vitro activity of taurolidine agains
- GlobeNewswire
CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
BERKELEY HEIGHTS, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be giving a company presentation at the Cantor Fitzgerald Global Healthcare Conference being held in New York City on September 26 – 28, 2023. Cantor Fitzgerald Global Healthcare Conference Date:Thursday,
- GlobeNewswire
CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology
BERKELEY HEIGHTS, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the publication of its Phase 3 LOCK IT-100 study results in the Clinical Journal of the American Society of Nephrology, or CJASN. The study compared the efficacy and safety of DefenCath®, a catheter lock solution that combines
